Kornimate/medical-research-clean huggingface dataset:
vacuum cupping for chronic neck and back pain

Conditions: Chronic Pain; Neck Pain; Back Pain

Summary: small clinical pilot studies have shown that vacuum massage-related techniques such as traditional dry cupping can reduce musculoskeletal pain such as back and neck pain. at the same time, little is yet known about the potential mechanisms of action of these therapies. a vacuum pump induces a massaging effect of the skin including the deeper tissue layers. the resulting massage technique corresponds to a kind of tissue manipulation similar to dry cupping. in this procedure, suction force and air flow can be individually adjusted. this is an advantage that can be used for patients with varying degrees of sensitivity or who are preloaded by patients with varying degrees of sensitivity or a history of pain. the aim of this study was to test the feasibility of the study design.


Eligibility criteria:
inclusion criteria: * chronic neck or back pain * mean pain intensity ≥ 40 mm vas exclusion criteria: * neurological symptoms or neuropathic pain * vertebral column surgery less than 12 months prior to the study * tens, acupuncture, osteopathy, or a chiropractic maneuvre or infiltration at the area within 4 weeks prior to the inclusion in the study * congenital deformation of the spine

Keywords: vacuum cupping quantitative sensory testing
neuronavigation rtms to improve depressive episodes of bipolar disorder in adolescent

Conditions: Bipolar Disorder

Summary: the purpose of this study is to explore a new stimulation target and protocol for the treatment of depressive episode in adolescents with bipolar disorder through the repetitive transcranial magnetic stimulation(rtms) under neuronavigation, and verify whether there is abnormal functional connectivity between the emotion-related brain area orbital frontal lobe (ofc) and the primary visual cortex(v1) during the depressive episode, which will contribute to further understand the relevant neural pathway and mechanism.


Eligibility criteria:
inclusion criteria: 1. age 14-28 years old, regardless of gender; 2. meet dsm-v diagnostic criteria for bipolar depressive episodes; 3. young mania rating scale (ymrs) ≤ 6 points; 4. mards:12-30 points. 5. han nationality, right-handed; 6. more than 9 years of education. exclusion criteria: 1. history of severe somatic or brain organic diseases and craniocerebral trauma; 2. abnormal brain structure or any mri contraindications were found by magnetic resonance examination; 3. those who do not cooperate or cannot effectively complete the experiment; 4. drug, alcohol or other psychoactive substance abusers; 5. pregnant, lactating or planned pregnancy. 6. severe suicidal ideation and behavior 7. ect or rtms treatment was performed within six months
risk factors for asthma in laboratory animal allergy

Conditions: Asthma; Lung Diseases

Summary: to identify risk factors which predispose individuals to develop asthma and other manifestations of allergic disease on exposure to laboratory animals in the workplace.

background: in 1982, asthma and allergy to laboratory animals among persons who worked with the animals gained increased recognition as an occupational health problem affecting researchers, veterinarians, technicians, animal handlers, and others. at that time, more than 90,000 workers across the united states were at risk due to their exposure to lab animals in the more than 1,100 facilities registered by the united states department of agriculture. several surveys of exposed workers indicated a prevalence rate of allergic symptoms due to laboratory animal allergy ranging from 19-30 percent in animal workers. asthma was also a frequent disease among animal workers; these surveys indicated that as many as 13-14 percent of exposed workers had asthma. the problem of laboratory animal allergy and asthma involved a vast industry that included medical and veterinary colleges, research institutes and universities, pharmaceutical manufacturers, commercial laboratory animal producers, and hospitals. design narrative: recruitment for this longitudinal study began in november 1983 and ended in july 1987. the initial visit consisted of an extensive interview to identify and to exclude those individuals with laboratory animal allergy, asthma, and other manifestations of allergy and to obtain an occupational history. venipuncture was used to obtain serum for ige and igg antibody assays. pulmonary function tests, including a methacholine challenge, were administered. psychosocial questionnaires were administered. subjects were evaluated at six month intervals with skin tests, venipuncture, and methacholine challenge. the degree of exposure to animal allergens was quantitated by aeroallergen sampling of workplace and personal breathing zone air and by work diaries. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
clinical outcomes of peroral endoscopic myotomy

Conditions: Achalasia

Summary: esophageal outflow obstruction is characterized by failure to relax the lower esophageal sphincter (les), resulting in impaired flow of ingested food into the stomach. the subsequent stasis of ingested food leads to symptoms of dysphagia, regurgitation, chest pain, and weight loss. the core objective of the treatment of esophageal outflow obstruction is to disrupt the les and reduce its pressure to allow esophageal emptying. therapeutic options include pharmacologic therapy, botulinum toxin injection, pneumatic balloon dilation, and surgical myotomy with partial fundoplication. in addition, peroral endoscopy myotomy (poem) has recently been introduced as a minimally invasive treatment, but there have a few studies regarding long-term outcomes. the aim of this study is to evaluate clinical outcomes of poem for esophageal outflow obstruction.

prospective study

Eligibility criteria:
inclusion criteria: * patients who were diagnosed as esophageal outflow obstruction * patients with informed consent exclusion criteria: * diagnostic uncertainty * patients who are not suitable for general anesthesia

Keywords: achalasia poem outcome
probiotic chocolate study in multiple sclerosis

Conditions: Multiple Sclerosis; Healthy Nutrition

Summary: the goal of this study is to assess the effects of probiotics on persons with multiple sclerosis (ms), persons at higher genetic risk for ms (first degree family members of persons with ms), and healthy controls. participants will be asked to consume probiotic containing chocolates (bouchard belgian dark chocolate probiotic napolitains containing 10 billion cfus of bifidobacterium longum per day) for 6 weeks. participants will undergo blood draws before and after the 6 weeks of probiotic containing chocolate and microbial metabolites and immune markers will be compared before and after the probiotics, as well as between groups.

the goal of this study is to assess the effects of probiotics in persons with ms (pwms), persons at high genetic risk for ms (first degree family members of pwms), and healthy controls. pwms. subjects undergo blood draws and will complete surveys on neurological symptoms (as relevant). subjects are given a supply of individually wrapped probiotic containing chocolates (bouchard belgian dark chocolate probiotic napolitains) along with instructions on proper storage, dosage, and a diary to complete regarding supplement adherence. after a "ramp up" period of 3 days during which participants will consume take 2 chocolates per day, participants consume 5 chocolates per day (10 billion cfus of bifidobacterium longum per day) for 6 weeks. after 6 weeks participants return the adherence diaries and answer questions about probiotic tolerance. they also repeat similar surveys and again undergo blood draws. serum levels of microbial metabolites and peripheral blood immune profiles are assessed before and after supplementation.

Eligibility criteria:
inclusion criteria: * multiple sclerosis (ms) subjects, first-degree relatives of ms subjects, or healthy controls * age 18-45 exclusion criteria: * diabetes * tree nut allergy * pregnancy

Keywords: muliple sclerosis probiotic
crossover study with multihance vs a comparator for peripheral mra

Conditions: Peripheral Vascular Disease

Summary: this is a double blind crossover study designed to compare two different gadolinium products given at the same dose to patients undergoing mra assessment of lower legs for the evaluation of peripheral steno-occlusive disease.


Eligibility criteria:
inclusion criteria: * written informed consent * at least 18 yrs of age * moderate to severe peripheral arterial disease * willing to undergo two mra procedures within 14 days exclusion criteria: * pregnant or lactating * known allergies to one or more ingredients in the products * therapeutic intervention in the arterial territory of interest between the two mra exams * changes in symptoms between the two exams * vascular stent in area of interest * severe claustrophobia * congestive heart failure class iv * scheduled to undergo surgery for paod between the two exams * scheduled to undergo dsa between the two exams
observation of use of claritin (loratadine) tablet, reditabs, and dry syrup in children (study p05834)(completed)

Conditions: Rhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial; Urticaria; Pruritus

Summary: the purpose of this study is to collect information on unexpected adverse reactions (adrs), how often adrs occur, and factors that can affect the safety and effectiveness of claritin (loratadine) when used in children. patients will be observed while they are taking claritin, and adrs and symptom scores will be recorded. at the end of treatment, improvement in symptoms will be recorded. post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. the results will be submitted to public health officials as required by applicable national and international laws.


Eligibility criteria:
inclusion criteria: * pediatric patients aged 3 to 15 years who are treated with claritin for any of the following reasons: allergic rhinitis, urticaria, itching due to skin disease (eczema, dermatitis, or pruritus cutaneous) exclusion criteria: * (none)
extension study of tanezumab in osteoarthritis

Conditions: Osteoarthritis

Summary: safety extension study of phase 3 osteoarthritis trials with tanezumab

this study was terminated on 27 october 2010 following a us fda clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 june 2010 for potential safety issues.

Eligibility criteria:
inclusion criteria: * must have participated in previous (specific) phase 3 trials of tanezumab in osteoarthritis exclusion criteria: * willing to comply with scheduled visits and treatment plan is medically fit to participate in the trial in the judgement of the investigator

Keywords: tanezumab oa arthritis
evaluation of the reproducibility of a fatigability test fitted to patients with spinal muscular atrophy

Conditions: Spinal Amyotrophy; Infantile Spinal Muscular Atrophy; Juvenile Spinal Muscular Atrophy

Summary: spinal muscular atrophy (sma) is an autosomal recessive neuromuscular disease caused by the degeneration of motor neurons in the anterior horn of the spinal cord, due to the absence of the smn1 gene and the resulting lack of smn protein. some patients with particularly severe forms (types 0 or 1) die before the age of 2 in the absence of treatment, while others retain autonomous walking throughout their lives, with no reduction in life expectancy. three treatments aimed at restoring smn (trs) protein expression have recently been approved by the us food and drug administration and the european medicines agency (i.e. nusinersen / onasemnogene abeparvovec / risdiplam). patients treated with trs after the onset of symptoms (symptomatic patients) may show significant motor improvement, but retain difficulties such as muscle weakness and fatigue leading to limitations in activities of daily living. the aim of this study is to adapt a fatigability test, widely validated in its original version in different populations (qif test), but adapted in this protocol to the motor level and low abilities of certain sma patients. our objectives are to determine whether these assessments are feasible in sma patients, reproducible, and relevant for monitoring this population, either routinely or for future clinical trials.


Eligibility criteria:
inclusion criteria: * genetically confirmed spinal muscular atrophy * age ≥ 6 years * no orthopaedic surgery in the 6 months prior to inclusion * informed consent signed by the patient(s) or parent(s)/legal guardian(s) and assent of the patient * affiliated or beneficiary of a health insurance scheme (for inclusion in france) exclusion criteria: * other condition that may significantly interfere with the assessment of the sma and which is clearly unrelated to the disease * other associated neurological disease * joint deformities that prevent correct and comfortable positioning with the various different measuring devices (thumb-index clamp, handgrip and qif-test) * contraindication to transcranial magnetic stimulation

Keywords: spinal muscle atrophy neuromuscular performance fatigue peripheral fatigue
rescue antenatal steroids and pulmonary function tests in preterm infants

Conditions: Respiratory Compliance; Functional Residual Capacity; Pulmonary Function Testing

Summary: one course of steroids given to a mother before a premature delivery helps the lungs of the premature infant and decreases breathing problems. one course of antenatal steroids is the standard of care for threatened premature deliveries. it is unclear as to how long the benefit of one course of steroids last. the most benefit to the baby's lungs seem to occur if the steroids are given at least 24 hours before but within 7 days of a premature delivery. it is difficult to predict the timing of a preterm delivery so deliveries often do not occur within this time period. we hypothesize that the benefits of the steroids to the lungs wear off if the steroids are given more than 14 days before a preterm delivery, and that in these circumstances an extra course of steroids will help the premature baby's lungs and the premature baby will have less breathing problems as shown by lung function testing.

the primary purpose of this randomized, blinded placebo controlled trial is to quantify and compare measurements of pulmonary function (including respiratory compliance and lung volumes/functional residual capacity) of hospitalized preterm infants whose mothers received an initial course of antenatal corticosteroids, remained undelivered after 14 days and at \< 34 weeks of gestation, and were then randomized to either a rescue course of antenatal corticosteroids or to a rescue course of placebo. in addition, follow-up pulmonary function tests, clinical outcomes, growth parameters, and the neurodevelopmental outcome of these infants will be followed.

Eligibility criteria:
inclusion criteria: * greater than 14 days after first course of antenatal steroids; * less than 34 weeks of gestation; * identified by primary physician as continued risk for preterm delivery; * informed consent exclusion criteria: * major congenital anomalies * multiple gestation of triplets or greater * mother with insulin dependent diabetes

Keywords: premature delivery respiratory distress syndrome
bt-010 registry for the evaluation of safety and clinical outcomes in patients treated with botulinum antitoxin

Conditions: Botulism

Summary: the purpose of the registry was to evaluate patient safety following botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine) (bat®) administration in adult and pediatric patients with a confirmed or suspected exposure to botulinum toxin.

a full description of the patient registry can be found in the paper titled: safety and clinical outcomes of an equine-derived heptavalent botulinum antitoxin treatment for confirmed or suspected botulism in the united states. richardson js, parrera gs, astacio h, sahota h, anderson dm, hall c, babinchak t. clin infect dis. 2019 apr 15;70(9):1950-1957.

Eligibility criteria:
inclusion criteria: * any patient of any age \[age category: pediatric-newborn infants (0 to 27 days), infants and toddlers (28 days to 23 months), children (2 to 11-years), and adolescents (12 to \<17-years); adult (17-64-years); and geriatric (≥65-years)\] with a confirmed or suspected exposure to botulinum toxin who were treated with bat® provided by the cdc. exclusion criteria: * none.

Keywords: registry botulinum antitoxin botulism antitoxin heptavalent- (equine) bat®
opioid-free orthopaedic surgery

Conditions: Pain Management

Summary: to compare the safety and effectiveness of two pain control pathways following routine orthopaedic surgical procedures (single level or two-level acdf/acda, 1st cmc arthroplasty, hallux valgus/rigidus corrections, diagnostic knee arthroscopies, total hip arthroplasty, and total shoulder arthroplasty / reverse total shoulder arthroplasty). the control group will undergo surgery with an opioid-based pain protocol and the intervention group will undergo surgery with a multimodal, opioid-free protocol. patients will have data collected with respect to pain scores, overall comfort level, overall satisfaction with the surgical experience and recovery, constipation, falls, and overall satisfaction with pain control, in addition to procedure-specific outcome scores and patient-specific metrics.


Eligibility criteria:
inclusion criteria 1. patient is scheduled to undergo one of the following procedures: * primary single-level or two-level acdf or acda for degenerative disease * primary 1st cmc arthroplasty * primary hallux valgus or hallux rigidus correction * diagnostic knee arthroscopy +/- meniscal debridement * elective primary total shoulder or reverse total shoulder arthroplasty * primary total hip arthroplasty exclusion criteria 1. revision surgery for one of the study-specific procedures 2. chronic opioid therapy - per investigator discretion 3. significant liver disease - (note: patients with a history of liver disease will have a hepatic panel drawn to be reviewed by the study investigator to asses if the values are within acceptable limits for inclusion in the study) 4. fracture or soft tissue injury 5. sickle cell disease 6. workers compensation 7. alcohol dependence 8. contra-indication to regional anesthesia 9. history of gastrointestinal (gi) bleeding or peptic ulcer 10. history of bleeding problems 11. patients taking anticoagulants, not including aspirin (only applies to randomized portion of study. these patients can still participate in observational control group) 12. renal insufficiency - creatinine clearance less than 30 ml/min (only applies to patients having surgery requiring nsaids treatment) 13. outpatient tha or tsa/rtsa 14. hammertoe in isolation (hallux valgus/rigidus exclusion only) 15. concomitant meniscal repair or microfracture (knee arthroscopy exclusion only) 16. ineligible for spinal anesthesia (tha exclusion only) 17. previous ipsilateral hip surgery, not including hip scope (tha exclusion only) 18. allergy to non-steroidal anti-inflammatory medications (nsaids)
home-monitoring in implantable cardioverter defibrillator (icd) patients

Conditions: Ventricular Arrythmias

Summary: the purpose of this study is to investigate the cost-effectiveness and effectiveness of remote-monitoring compared to standard care in patients with implantable cardioverter defibrillator.

implantable cardioverter defibrillator (icd) are an important and effective treatment in patients at risk of sudden cardiac death. in order to allow for a more continuous follow-up and reduced complication rates of patients with icd, new devices including remote-monitoring (home-monitoring) features of patients with icd have been developed. biotronik home monitoring service enables the doctors to safely follow up their patients with implanted cardioverter-defibrillators in a remote fashion, with fewer in-clinic consultations. this may result in a more efficient follow-up and cost-savings for the health care payer. the objective of the current study is to investigate the cost-effectiveness and effectiveness of home-monitoring compared to standard care.

Eligibility criteria:
inclusion criteria: * the patient is willing/able to undergo the study protocol appointments and procedures/questionnaires * indication for implantation of single chamber icd or dual chamber icd according to european guidelines exclusion criteria: * age \ 80 years * expected non-compliance * known drug or alcohol abuse * life expectancy \< 1 year * nyha classification iv * participation in another clinical study * participation in another telemonitoring concept * pregnant or breast-feeding woman * uncontrolled hypertension * no mobile phone use possible in patient residence

Keywords: patients with ventricular arrhythmias and the prevention of sudden cardiac death
tucidinostat plus pd-1 inhibitor and bevacizumab for advanced esophagus cancer, aeg, gastric cancer

Conditions: Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma

Summary: this phase ii study was designed to assess the efficacy and safety of the combination of pd-1 inhibitor, tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced esophageal squamous cell cancer, adenocarcinoma of esophagogastric junction, gastric adenocarcinoma patients.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years, ≤ 75 years 2. histologically or cytologically confirmed esophageal squamous cell cancer, adenocarcinoma of esophagogastric junction and gastric adenocarcinoma, unresectable, recurrent or metastatic disease. 3. can provide at least 5 pieces of pathological section or fresh tumor tissue 4. eastern collaborative oncology group (ecog) ≤ 1. 5. ≤2 systemic chemotherapy for advanced disease (total number of treatment lines for advanced disease ≤4). 6. patients who have previously used pd-1 antibodies, pd-l1 antibodies, pd-l2 antibodies, or ctla-4 antibodies (or any other antibodies acting on t cell co-stimulation or checkpoint pathways) or require a duration of ≥16 weeks; 7. adequate organ function. 8. life expectancy is more than 3 months. 9. for females of child bearing potential, a negative urine or serum pregnancy test result within 3 days before study treatment. 10. willing and able to provide written informed consent. exclusion criteria: 1. allergies to any monoclonal antibody or tucidinostat preparation have been known, and hypersensitivity reactions of more than 3 levels have occurred 2. previously received immunotherapy and had grade 3 or above immune-related adverse events. 3. previously received histone deacetylase inhibitors,or toripalimab, or angiogenesis inhibitors. 4. subjects with any active, known or suspected autoimmune disease or history of autoimmune disease. 5. known active cns metastases and/or carcinomatous meningitis. 6. received a live vaccine within 4 weeks of the first dose of study medication. 7. major surgery received or severe traumatic injury, fracture, or ulcer occurred within 4 weeks of the first dose of study medication. 8. pregnant or lactating female. 9. uncontrolled clinically significant systemic diseases, including active infection, unstable angina, angina occurred within 3 months,≥ nyha ii congestive heart failure, myocardial infarction occurred within 6 months, severe arrhythmia, liver, kidney, or metabolic disease. 10. participate in other clinical trials currently or within 4 weeks prior to enrollment.